Fresenius Medical Care AG increases its investment in Humacyte
Fresenius Medical Care AG has invested an additional $25 million in clinical-stage biotechnology platform company Humacyte Inc., following an initial investment of $150 million made in 2018.
Humacyte is developing implantable human acellular vessels that are being evaluated in a clinical trial for use during hemodialysis, according to a press release.
“Humacyte’s regenerative medicine technology has great potential in many areas of health care,” Franklin W. Maddux, MD, global chief medical officer of Fresenius Medical Care AG (FMC AG), said in the release. “We are committed to helping Humacyte achieve market approvals with this renewed investment, to bring their technology into the mainstream of health delivery. This will bring benefits worldwide in the care of patients needing repair or reconstruction of the human vasculature.”
Humacyte is developing the implantable vessels for multiple vascular repairs, reconstruction and replacement. These vessels are biologically produced blood vessels made from banked, human, smooth muscle cells; the vessels “are manufactured to be non- immunogenic and are to be available ‘off the shelf’ when needed by a patient,” according to the release.
With its investment, FMC AG was granted exclusive rights to market the human acellular vessel outside the United States, including enhancements and modifications for vascular trauma applications. In addition, the company will be able to market the device for vascular access and peripheral arterial disease applications, according to the release.